Proactive - Interviews for investors

hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candidate using the hVIVO Human Rhinovirus Human Challenge Study Model.

The Phase 2a clinical trial is designed as a randomised, double-blinded, placebo-controlled human challenge study and will be conducted at hVIVO's advanced quarantine facilities in Canary Wharf. The primary objective of this study is to assess the impact of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against Human Rhinovirus (HRV) infection in various groups of healthy volunteers.

Catchpole explained that the study is scheduled to begin in the second half of 2024, with revenue recognition spread across 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers who will be subjected to controlled HRV infection. The biotechnology client recognizes the value of human challenge studies in rapidly generating early human efficacy data, which has the potential to significantly enhance the clinical asset's overall value.

Catchpole says the contract underscores hVIVO's expertise in conducting human challenge studies and its growing role in helping pharmaceutical and biotechnology companies evaluate the effectiveness of their antiviral treatments.

#proactiveinvestors #hvivoplc #aim #hvo #clinicaltrial #antiviralcandidate #humanchallengestudy #biotechnology #rhinovirus #medicalresearch #humantesting #viralload #pharmaceuticals #medicalstudies #clinicalasset #clinicalcontact

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Sigma Lithium CEO Ana Cabral-Gardner joined Steve Darling from Proactive announcing the company's final shipment for 2023 of Quintuple Zero Green Lithium concentrate. This marks the end of a truly transformative year for the company.

Cabral-Gardner explained that the fifth shipment of sustainable lithium concentrate is en route to Glencore at the Port of Vitoria and is expected to arrive before the end of the year. Glencore has agreed to prepay 50% of the shipment's value upon completion of loading. This prepayment reflects a provisional premium price for Sigma Lithium's unique Quintuple Zero Green Lithium concentrate.

Over the past twelve months, Sigma Lithium has achieved remarkable milestones, from successfully commissioning the crushing unit in December 2022 on schedule and within budget to sustaining nameplate production levels at its Greentech lithium concentrate plant in December 2023. These operating rates support a monthly shipment cadence of approximately 22,000 tonnes throughout 2024, equivalent to an annual output of approximately 270,000 tonnes of Quintuple Zero Green Lithium concentrate. This achievement underscores the company's significant progress and commitment to sustainable lithium production.

#proactiveinvestors #nasdaq #sgml #tsxv #sgml

#SigmaLithium #GreenTech #LithiumProduction #SustainableMining #CleanEnergy #EnvironmentalInnovation #MiningTechnology #RenewablePower #ZeroEmissions #YearInReview #MiningIndustry #EcoFriendly #BatteryMaterials #MineralResources #CleanTech #InnovationInMining #FutureExpansion #GlobalLithiumProducer #EconomicSuccess #TeamCollaboration #EnvironmentallySustainable #MiningInnovation #CarbonNeutral #ResourceUpgrade #YearEndReview

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tonix Pharmaceuticals CEO Dr. Seth Lederman recently recently shared groundbreaking news during an interview with Steve Darling from Proactive. The company has achieved highly positive results in their clinical trial targeting Fibromyalgia, a chronic pain disorder affecting approximately 10 million Americans and for which satisfactory treatments are often lacking.

TNX 102 SL, Tonix's drug candidate, demonstrated remarkable efficacy in the second phase three clinical trial. The primary pain endpoint achieved an exceptionally low p-value of 0.00005. What's even more promising is that TNX 102 SL is a non-opioid medication with no recognized addictive potential. In addition to addressing pain, the drug also effectively tackled other Fibromyalgia symptoms such as fatigue and sleep disturbances.

Lederman informed Proactive that the company's next steps involve filing a new drug application (NDA) for FDA approval. They anticipate a pre-NDA meeting scheduled for the first half of 2024. This groundbreaking development places Tonix Pharmaceuticals at the forefront of Fibromyalgia treatment innovation, providing hope to millions of individuals suffering from the condition. Further updates on this transformative drug are eagerly anticipated in 2024.

#proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp

#FibromyalgiaTreatment #HealthcareInnovation #ChronicPainRelief #TNX102SL #MedicalBreakthrough #ClinicalTrialSuccess #FDAApprovalJourney #PainManagement #HealthTechNews #DrugDevelopment #MedicalResearchUpdate #InnovativeMedicine #FightingFibromyalgia #NonOpioidSolution #MedicalAdvancements #PatientCare #HopeForHealth #PainFreeLiving #WellnessJourney #FutureOfMedicine #ScientificDiscovery #ClinicalTrialResults #CEOInterview #2025LaunchDate#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Spenda Ltd CEO Adrian Floate sits down with Jonathan Jackson in the Proactive studio to discuss the new 10-year service agreement with Capricorn. The company has been working on this Digital Services Delivery initiative with Capricorn over the last six months and Adrian looks at how the agreement came about and what comes next. The contract will generate $2 million in revenue in 2024 and has significant revenue potential over the long term. Capricorn has also announced a new partnership with eBev to offer integrated payment solutions across the hospitality supply chain. Floate introduces eBev and how Spenda’s solutions will improve the flow of payments across their network of buyers and sellers. Finally, he talks us through the different revenue streams that you Spenda will generate through these agreements and coming milestones and timelines.

#ProactiveInvestors #SpendaLtd #ASX #DigitalServicesDelivery #tech

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

CuFe Ltd CEO Mark Hancock joins Jonathan Jackson in the Proactive Australia studio to discuss the work being done ahead of the company’s maiden North Dam lithium and REE drill program in March 2024. The company remains on track for the program and has identified several drill targets. The company also continues to expand its leasehold, with a recent acquisition in the North Dam region. Hancock discusses the successes others have achieved around North Dam and the opportunities these successes may hold for CuFe in future. Finally, CuFe is also increasing its West Arunta project following recent niobium and REE discoveries.

#ProactiveInvestors #CuFeLtd #ASX #CriticalMinerals #RareEarthElements #Lithium

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Magnetite Mines CEO Tim Dobson sits down with Jonathan Jackson in the Proactive studio to discuss the formalisation of the ‘Walking Together – One Team Partnering Agreement’ with the Ngadjuri Nation Aboriginal Corporation, the Native Title holders of the land where Magnetite’s Razorback Iron Ore Project in South Australia is situated. The agreement is expected to yield long-lasting benefits for Magnetite and the Ngadjuri Community and resonates with Magnetite's advanced sustainability initiative. Dobson speaks about fostering a mutual dedication to equality, trust and culturally respectful practices with the Ngadjuri Community. The agreement has been two years in the making and the partners will work closely on the development of the Razorback and Iron Peak mines, including supporting infrastructure, future mining projects, exploration activities, land management and the economic and social progress relevant to Ngadjuri Country and interests.

#ProactiveInvestors #MagnetiteMines #ASX #Magnetite #RazorbackIronOreProject

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to discuss a significant development within the company. Voyageur Pharmaceuticals, in partnership with Rain Cage Carbon Inc., has achieved a major milestone in the field of medical imaging. Rain Cage Carbon Inc. has successfully completed Stage 1 testing of a new molecule known as metallofullerene, with profound implications for the radiology market. Metallofullerene, based on its unique molecular structure, holds the potential to be a safer alternative to existing drugs in the medical imaging industry.

Willis emphasized that this breakthrough is a significant step forward, as Metallofullerene has demonstrated its superiority as an MRI contrast agent compared to currently available options. What sets Voyageur apart is its exclusive access to fullerene and vanadium, granted by its drug development agreement with Rain Cage. This partnership not only eliminates sourcing costs but also entails a revenue-sharing arrangement between Voyageur and Rain Cage for future drug sales. Additionally, Voyageur holds the rights for carbon imaging drug development and sales in North America.

One intriguing aspect of this development is that the carbon and other minerals created through Rain Cage's technology are by-products of carbon capture from fossil fuel emissions. This positions Voyageur and Rain Cage to establish a versatile pipeline of new carbon-based drugs for diagnostic imaging. The pipeline may include combinations of iodine with fullerene and theranostic radiology drugs. Looking ahead, Voyageur Pharmaceuticals plans to initiate further testing on Vanadium for factors such as relaxivity and safety. These endeavors will commence upon securing financing, with the research and pre-clinical activities set to kick off in 2024. This marks an exciting phase for Voyageur as they continue to advance their presence in the field of medical imaging and drug development.

Dolly Varden Silver CEO Shawn Khunkhun recently joined Steve Darling from Proactive to share a significant development for the company entering into an option agreement, which allows them to earn 100% interest in the southern portion of the Big Bulk Project from Libero. This strategic move consolidates the entire copper-gold porphyry system, significantly enhancing the company's prospects in the region.

The Libero property, known as the Big Bulk Property, encompasses seven mineral claims, spanning over 3,000 hectares within the Golden Triangle of British Columbia. Importantly, the property already holds existing land use agreements and exploration permits, streamlining Dolly Varden Silver's exploration efforts. Khunkhun elaborated that the southern part of the Big Bulk Property has a history of exploration dating back to 2001-2003 when Teck and Canadian Empire Minerals were actively involved. Recent geologic mapping has led to a new interpretation of the geology, revealing a larger calc-alkaline porphyry system with structural similarities to the Kerr-Sulpherets-Mitchell deposits, displaying comparable age and setting.

Regarding their plans for 2024, Khunkhun mentioned that they have 70 drill holes set to report in the new year. The objective is to connect deposits, potentially marking a watershed moment for Dolly Varden Silver. Khunkhun believes that they are already at a point where they have significant size and grade, and the next round of drilling could be transformative. Their 2024 plans include continuing to delineate resources, expanding and extending their deposits, and answering the question of whether they have a 1 billion-ounce Silver Cow on their hands, as they are 14% of the way there based on their 2019 results and 100,000 meters of drilling. The geological similarities with nearby world-famous mines like SK, Bruce Jack, Kennedy, and Premier make this a compelling prospect.

Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Thomas Warner from Proactive after the wellness and recreational products company announced the signing of a deal with an unspecified top-five UK supermarket to stock Chill Brands' nicotine-free vape products in over 1500 of its stores.

The deal brings Chill Brands' UK stockist count to over 2100 outlets and Sommerton expects the deal to help push revenues past the £2 million mark before long.

Sommerton says that 2023 was a transformative year for Chill Brands, with a shift away from legacy CBD products towards nicotine-free offerings like Chill ZERO, both in the US and UK. The company also launched an online marketplace, Chill.com, hosting over 40 brands, and plans to continue expanding in 2024. A notable partnership with Smoker Friendly will introduce Chill ZERO in various US states.

The interview concludes with Sommerton reflecting on growth in Chill's share price, attributing it to persistent effort and the strategic pivot.

#ChillBrands #CallumSommerton #ProactivInterview #NicotineFreeVape #UKRetailDeal #ChillZero #CBDProducts #VapeIndustry #UKSupermarkets #RetailExpansion #SmokerFriendly #SugarCalmMarketplace #BusinessStrategy #CompanyGrowth #FinancialMilestones #ECommerce #AmazonUK #EuropeanMarketExpansion #StockMarket #SharePriceGrowth #BusinessTransformation #CEOInterview #BusinessNews #VapingTrends #RetailStrategy #2023BusinessReview #ProactiveInvestors #chill #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Europa Oil & Gas (Holdings) PLC (AIM:EOG) chief executive William Holland speaks to Thomas Warner from Proactive after the exploration and production company announced the acquisition of a 42.9% interest in Antler Global, which in turn owns an 80% stake in the EG-08 gas asset offshore Equatorial Guinea.

Holland says that the venture, strategically chosen for its geological and geographical familiarity, along with strong in-country connections, represents a compelling value with a high risk-reward balance.

Adjacent to a Chevron-operated gas field, the asset includes three gas prospects totalling 1.4 trillion cubic feet (TCF) and Holland suggests they each offer a 60-70% chance of exploration success. Holland emphasises the unique seismic response of these sites, boosting the probability of economic discovery to over 90%.

He says the project, requiring an estimated $40-50 million investment, is particularly attractive for major oil companies to farm into due to its high-quality data, clear seismic responses, and proximity to existing infrastructure.

Holland credits the deal's success to Europa's strategic relationships in the industry. The company aims to farm out the operational aspect, focusing on other prospects at deeper levels within the license, which hold further potential. This strategy aligns with Holland's broader vision for the company, which includes ongoing projects in the UK and Ireland.

#EuropaOilAndGas #OilAndGasIndustry #EquatorialGuinea #EnergySector #NaturalGasExploration #ChevronAdjacentFields #SeismicTechnology #OilAndGasExploration #EnergyInvestment #OilIndustryNews #OilAndGasAcquisition #ExplorationSuccess #OilAndGasInnovation #EnergyProspects #EnergyMarketUpdate #GlobalEnergyTrends #WillHollandCEO #ProactivInterview #OilAndGasStrategies #EnergyInfrastructure

#ProactiveInvestors #oil #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews